BioPhy, Jana Care, Kythera Labs
Betterleave Raises $2.4M in Seed Funding
Betterleave, an Austin, TX-based provider of a platform that partners with organizations to improve access, experience, and outcomes, while lowering the total cost of bereavement care, raised $2.4M in Seed funding.
The round was led by Chingona Ventures, with participation from Bread and Butter Ventures, Vitalize VC, Wisdom Ventures Fund, Coyote Ventures and AARP.
The company intends to use the funds to expand its clinical care model and refine its grief training curriculum to meet the growing demand over the coming months.
Led by Cara McCarty Abbott, founder and CEO, and Sam Leung, Head of Product, Betterleave offers a platform that provides comprehensive bereavement care support to individuals and organizations. With a focus on grief and mental health, it allows personalized administrative and counseling services, helping individuals navigate the complex challenges of grief and loss. The platform specializes in various types of grief, including but not limited to the loss of a loved one, pregnancy loss, pet loss, anticipatory loss and relationship loss. Betterleave also supports patients and caregivers, facilitating the transfer of critical information via programmatically sent messages and family collaboration features.
Betterleave Raises $2.4M in Seed Funding
Betterleave, an Austin, TX-based provider of a platform that partners with organizations to improve access, experience, and outcomes, while lowering the total cost of bereavement care, raised $2.4M in Seed funding
BioPhy Raises $4.5M in Funding
BioPhy, a Philadelphia, PA-based company providing an AI operating system to advance promising drug candidates, raised $4.5M in funding.
The round was led by Chelsea Clinton and Caroline Kassie’s Metodora Ventures, Audere Capital, and TRCM, as well as Jeff Marrazzo, the Co-Founder of Spark Therapeutics.
The company intends to use the funds to expand its R&D sector, operations and its business reach.
Led by CEO Dave Latshaw II, BioPhy is working to transforming the way promising drugs are identified, developed, and tested. With its patent-pending predictive AI engine, BioPhy is focused on enhanceing the outcomes of clinical trials, reducing failure rates and accelerating the pace of developing new drugs with the goal of improving the quality of healthcare outcomes across the globe.
BioPhy works with pharmaceutical and life science companies, including innovators like Ambrose Healthcare, to identify promising target/drug opportunities and design their clinical trials. Its AI operating system for drug development currently consists of two products:
BioPhyRx: a generative AI solution designed to create a centralized, intuitive environment for accessing scientific and regulatory resources. Using large language models, this platform helps pharmaceutical companies in all stages of development by analyzing and interpreting scientific literature, clinical trials, regulatory guidelines and submissions, quality assurance documents, and other industry-specific sources to provide accurate and up-to-date information on demand. BioLogicAI: a predictive AI engine that provides customized insights to aid life science companies through all stages of the drug development process including clinical trial endpoint predictability, indication selection, licensing, drug repurposing, asset acquisitions, and divestment. BioLogicAI also benchmarks the biological feasibility of preclinical assets against those in development or already approved by the FDA.
BioPhy Raises $4.5M in Funding
BioPhy, a Philadelphia, PA-based company providing an AI operating system to advance promising drug candidates, raised $4.5M in funding
Nema Health, A Virtual PTSD Treatment Program, Raises $4.1M Seed Round And Launches In 3 States
Nema Health (Nema), a virtual treatment program delivering evidence-based care for post-traumatic stress disorder (PTSD), announced today it has closed a $4.1 million seed round. The fundraise was co-led by Optum Ventures and .406 Ventures, with participation from GreyMatter Capital and additional angel investors. Nema also announced the launch of its care program in New York, New Jersey and Connecticut with a national insurance partner.
Trauma and PTSD are one of the country’s most prevalent mental illnesses: an estimated 1 in 11 Americans will be diagnosed with PTSD in their lifetime, suffering from flashbacks, nightmares, self-blame, and significant mood changes after a traumatic event. Although PTSD is often associated with veterans, the most common traumas that cause PTSD are rape and intimate partner violence, and women are twice as likely to develop the condition. While effective treatment exists for PTSD, the majority of survivors go untreated because of cost barriers or a scarcity of healthcare providers trained in trauma care. These survivors then languish, developing related physical and mental health issues that incur a significant cost burden on the healthcare system.
Nema’s virtual platform provides access to effective trauma care and wraparound support to survivors, providing them a care team including a therapist, peer mentor, case manager, and psychiatrist when indicated. Nema’s clinical approach empowers survivors to reach durable, long-lasting recovery: about 75% of patients no longer meet the criteria for PTSD after just four weeks of intensive treatment with Nema.
Nema Health, A Virtual PTSD Treatment Program, Raises $4.1M
NEW HAVEN, Conn., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Nema Health (Nema), a virtual treatment program delivering evidence-based care for post-traumatic...
Jana Care raises $6m for commercialisation of self-administered blood tests
Jana Care has raised $6m in the Series B financing round, to complete the commercialisation of its self-administered blood tests for kidney and heart disease.
The financing round saw participation from both new and existing venture corporations, with IAG Capital Partners becoming the new lead investor that joined the investor syndicate and global strategic partners to support the development of Jana Care’s blood testing platform.
Jana Care intends to use the funds for further development of its quantitative blood testing platform.
The platform is intended to facilitate self-administered blood tests at home, enabling clinicians to remotely review the test results as required. The platform’s features are designed to address the challenges of distance and socioeconomic barriers that hinder the timely detection and monitoring of chronic kidney and heart disease progression.
Jana Care raises $6m to advance commercialisation of blood tests
Jana Care has raised $6m in the Series B financing round to complete the commercialisation of its self-administered blood tests
Kythera Labs Raises $20M in Funding
Kythera Labs, a Franklin, TN-based healthcare technology and data analytics company, raised $20M in funding.
The round was led by BIP Ventures and CIBC.
The company intends to use the funds for the continued growth and scale of Wayfinder, its data-transforming technology platform, and accelerate the development and adoption of new and existing offerings. Kythera also plans to leverage financing to expand partnerships with industry leaders such as Datavant and Databricks.
Led by CEO Jeff McDonald, Kythera Labs is a data and technology company that enables Healthcare and Life Sciences organizations to integrate, access, and analyze healthcare data with scale and speed using the Wayfinder data science platform and pre-configured data pipelines, data science toolkits, and remastered data sets for competitive advantages across markets.
Wayfinder, built on Databricks, supports enterprise-grade scalability. It corrects, enhances, and adds new dimensions to healthcare data, using a dynamically improving common data model that facilitates data integration. The platform provides access to real-world healthcare data spanning over 8 years, including over 320 million lives with 29.3 billion encounters.
Kythera Labs Raises $20M in Funding
Kythera Labs, a Franklin, TN-based healthcare technology and data analytics company, raised $20M in funding
Vida Health Raises $28.5M in Funding
Vida Health, a San Francisco, CA-based provider of virtual cardiometabolic care services, closed a $28.5m financing round.
The round was led by existing investors, including General Atlantic, Ally Bridge, Canvas Ventures, Hercules Capital, and other insiders.
The company intends to use the funds to further scale and pursue ongoing growth opportunities, particularly in the GLP-1 market.
Vida Health is a virtual cardiometabolic care company focused on treating diabetes and obesity with clinically validated programs that combine an AI-powered, personalized mobile app experience with a national network of providers who work in a care team model to maximize engagement, outcomes, and savings. The company’s app offers video sessions, asynchronous messaging, and digital content and programs to help people prevent and manage chronic conditions — like diabetes, obesity, and hypertension — and the mental conditions that accompany them — like stress, depression, and anxiety.
Vida Health Raises $28.5M in Funding
Vida Health, a San Francisco, CA-based provider of virtual cardiometabolic care services, closed a $28.5m financing round
Exclusive: Eleos Health banks $40M Series B to quantify therapy with voice
Eleos Health banks $40M Series B to quantify therapy with voice. Therapy voice analysis startup Eleos Health banked $40 million in Series B funding, CEO Alon Joffe tells Axios exclusively. Why it matters: The traditional therapy industry lacks technology-based tools to assess the efficacy of its treatments.
https://www.axios.com/pro/health-tech-deals/2023/11/08/eleos-health-raises-40m-series-b-quantify-therapy-voice-analysis-mental-health?mc_cid=58105c4e40&mc_eid=df5e82ed1d